Optum guides members and providers through important upcoming formulary updates. See multiple tabs of linked spreadsheet for Select, Premium & UM Changes.
Besremi®(ropeginterferon alfa-2b-njft) – New orphan drug approval
November 12, 2021 - the FDA announced the approval of PharmaEssentia’s Besremi (ropeginterferon alfa-2b-njft), for the treatment of adults with polycythemia vera.
